Menzies School of Health Research, Charles Darwin University, Australia; The University of Melbourne, Department of Medicine at Austin Health, Melbourne, Australia; Department of Endocrinology, Austin Health, Melbourne, Australia.
Menzies School of Health Research, Charles Darwin University, Australia; Baker Heart and Diabetes Institute, Melbourne, Australia.
J Diabetes Complications. 2019 May;33(5):343-349. doi: 10.1016/j.jdiacomp.2019.02.005. Epub 2019 Feb 21.
Glomerular hyperfiltration is not able to be detected in clinical practice. We assessed whether hyperfiltration is associated with albuminuria progression among Indigenous Australians at high risk of diabetes and kidney disease to determine its role in kidney disease progression.
Longitudinal observational study of Indigenous Australians aged ≥18 years recruited from >20 sites, across diabetes and/or kidney function strata. At baseline, iohexol clearance was used to measure glomerular filtration rate (mGFR) and hyperfiltration was defined as (i) a mGFR of ≥125 mL/min/1.73 m, and (ii) an age-adjusted definition, with the top 10% of the mGFR for each 10 year age group at baseline. Baseline and follow-up urine albumin-to-creatinine ratio (uACR) was collected, and linear regression was used to assess the associations of hyperfiltration and uACR at follow up.
407 individuals (33% men, mean age 47 years) were followed-up for a median of 3 years. At baseline, 234 had normoalbuminuria and 173 had albuminuria. Among participants with normoalbuminuria, those with mGFR ≥125 mL/min/1.73 m had 32% higher uACR at follow-up (p = 0.08), and those with age-adjusted hyperfiltration had 60% higher uACR (p = 0.037) compared to those who had normofiltration. These associations were independent of uACR at baseline, but attenuated by HbA. Associations were stronger among those without than those with albuminuria at baseline.
Although not available for assessment in current clinical practice, hyperfiltration may represent a marker of subsequent albuminuria progression among individuals who have not yet developed albuminuria.
肾小球高滤过在临床实践中无法被检测到。我们评估了肾小球高滤过是否与高危糖尿病和肾病的澳大利亚原住民的白蛋白尿进展有关,以确定其在肾病进展中的作用。
对来自 20 多个地点的年龄≥18 岁的澳大利亚原住民进行了一项横断面观察性研究,这些地点分为糖尿病和/或肾功能分层。在基线时,使用 iohexol 清除率来测量肾小球滤过率(mGFR),并将高滤过定义为:(i)mGFR≥125 mL/min/1.73 m,(ii)根据年龄调整的定义,即基线时每个 10 岁年龄组 mGFR 的前 10%。收集基线和随访时的尿白蛋白/肌酐比值(uACR),并使用线性回归来评估高滤过和随访时 uACR 的相关性。
407 名(33%为男性,平均年龄 47 岁)参与者的中位随访时间为 3 年。基线时,234 名参与者有正常白蛋白尿,173 名参与者有白蛋白尿。在正常白蛋白尿患者中,mGFR≥125 mL/min/1.73 m 的患者在随访时 uACR 增加了 32%(p=0.08),年龄调整后的高滤过患者 uACR 增加了 60%(p=0.037),与滤过正常的患者相比。这些相关性独立于基线时的 uACR,但被 HbA 减弱。在基线时没有白蛋白尿的患者中,这些相关性比基线时有白蛋白尿的患者更强。
虽然在当前的临床实践中无法评估,但高滤过可能是尚未出现白蛋白尿的个体随后发生白蛋白尿进展的标志物。